Gerontology & Geriatric Research

Powerful Treatment for Anti-aging Regimen

Jothi Vasudev^* Alliant International University, San Diego, California, USA
^*Correspondence: Jothi Vasudev, Alliant International University, San Diego, California, USA, Email:

Received: 11-Jan-2022, Manuscript No. jggr -22-15644; Editor assigned: 13-Apr-2022, Pre QC No. P-15644; Reviewed: 18-Apr-2022, QC No. Q-15644; Revised: 23-Jan-2022, Manuscript No. R-15644; Published: 28-Jan-2022, DOI: 10.35248/2167-7182.22.11.594

Editorial

The continual loss of an organism's homeostatic balance is defined as ageing. This multifactorial phenomenon appears to be influenced by both stochastic and genetically programmed mechanisms, and the same may be said for cellular senescence, one of the hallmarks of ageing. Because it is the contact between the organism and the environment, skin, the most voluminous "organ" of the body, exemplifies ageing owing to damage accumulation. As a result, cosmetic research is concentrating on the discovery of substances that combat skin ageing caused by extrinsic and intrinsic factors such as oxidative stress, photoaging caused by UV radiation, and so on. Natural products have traditionally been seen to be a promising source of medicinal chemicals, but a significant amount of research on the anti-aging effects of natural compounds has emerged in the recent decade.

In the early 1990s, anti-aging medicine emerged as a new specialty in medical practise. It has also been a more widely discussed and disputed topic in recent years. In geroscience, the development of anti-aging regimens aimed at aging-related functional decreases and disease symptoms is currently in the spotlight. Over the last 20 years, there has been an exponential increase in research in the subject of geriatric pharmacology, including the examination of potential antiaging medications. The selection of where the medicine targets is the first step in the drug research and discovery process. Anti-aging pharmaceuticals, such as renin-angiotensin-aldosterone system inhibitors, thiazolidinediones, and anti-inflammatory medications, are approved by the FDA and other regulatory agencies for the treatment of certain disorders. These medications are routinely used to treat patients with a variety of chronic medical diseases, and their efficacy and safety have been demonstrated in numerous clinical trials. They've also been demonstrated to promote health, physiological functioning, and well-being in people with chronic illnesses from middle age to old age. In the absence of clinical manifestations of illnesses, such medicines are currently not used in the treatment of age-related physiological dysfunctions. These drugs, on the other hand, may theoretically be redirected to treat or prevent aging-related illnesses or syndromes.

Because the target group can potentially act on another group, antiaging is undoubtedly one of the most promising sectors in modern pharmacy. Several supplements, such as resveratrol, are marketed as anti-aging pills in the pharmaceutical industry. Rapamycin, an antibiotic and immunosuppressant medicine licenced by the FDA, is based on this. Also, because ageing is linked to a certain amount of amyloid deposits, a medicine like melatonin can block the onset of inflammatory responses in a variety of ways, perhaps leading to additional anti-inflammatory characteristics. Most consumers are willing to pay for long-term pharmaceutical therapy to prevent or delay the aging-related loss in physical and mental functions, according to marketing studies. Recent sociological polls demonstrate that people all across the world want to live longer and be healthier. In the majority of surveys undertaken to date, life extension has been a result of an incorrect association of extended life with a protracted period of age-related functional decline and frailty [1-5].

Despite the popular belief that anti-aging therapy would raise the number of chronic patients in modern society, it would actually result in a decrease in the ratio of unwell to healthy persons, as it would delay the onset of age-related pathological disorders. In other words, it may result in a decrease in biological age (old people becoming biologically younger) and an increase in the age at which people become disabled. Also, whether the etiologies implicated generate a broad or narrow range of diseases, every preventive approach to ageing pathologies is an anti-aging treatment. For example, if a person had a leg injury, they might go to the hospital for treatment, which is nothing more than restoring normalcy in the sense of anti-aging.

REFERENCES

1. Ricci F, Bandello F, Navarra P, Staurenghi G, Stumpp M, Zarbin M. Neovascular Age-Related Macular Degeneration: Therapeutic Management and New-Upcoming Approaches. Int J Mol Sci. 2020;21:8242.

Google Scholar, Crossref, Indexed at

2. Spaide R. Ranibizumab according to need: A treatment for age-related macular degeneration. Am J Ophthalmol. 2007;143:679-680.

Google Scholar, Crossref

3. Ferris FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol. 1984;102:1640-1642.

Google Scholar, Crossref, Indexed at

4. Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: Applying clinical trial results to the treatment of everyday patients. Am J Ophthalmol. 2007;144:627-637.

Google Scholar, Crossref, Indexed at

5. Freund KB, Zweifel SA, Engelbert M. Do we need a new classification for choroidal neovascularization in age-related macular degeneration? Retina. 2010;30:1333-1349.

Google Scholar, Crossref, Indexed at